The latest update is out from Mural Oncology Plc ( (MURA) ).
On March 11, 2025, Mural Oncology announced its financial results for the fourth quarter and year-end 2024, highlighting a strategic focus on operational efficiency that extended their cash runway into Q1 2026. The company is preparing for significant clinical milestones in 2025, including interim data from the ARTISTRY-7 trial in ovarian cancer and top-line data from the ARTISTRY-6 trial in mucosal melanoma. These trials, involving their lead candidate nemvaleukin alfa, could impact Mural’s market positioning and offer potential value creation opportunities. Additionally, Mural expanded its pipeline with two new development candidates, MURA-8518 and MURA-7012, aimed at enhancing immune response and reducing toxicity.
More about Mural Oncology Plc
Mural Oncology is a clinical-stage immuno-oncology company focused on developing novel engineered therapies targeting cytokine pathways to address unmet needs in cancer treatment. Utilizing its protein engineering platform, the company aims to deliver cytokine-based immunotherapies that provide clinical benefits to cancer patients. Mural Oncology’s lead candidate, nemvaleukin alfa, is in potentially registrational trials for platinum-resistant ovarian cancer and mucosal melanoma.
YTD Price Performance: 13.44%
Average Trading Volume: 163,134
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $61.93M
For detailed information about MURA stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com